Testing HH-006 treatment for chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–45 years old and weigh at least 50 kg (men) or 45 kg (women), with a healthy BMI between 18–28
- You have had hepatitis B for at least 6 months, confirmed by blood tests or liver biopsy
- Your blood tests show specific hepatitis B levels that match one of three study groups
- You have not taken certain hepatitis B medications recently (timing varies by group)
- You do not have serious liver damage, cirrhosis, liver cancer, or other major organ diseases
- You are not pregnant, breastfeeding, or co-infected with hepatitis C, HIV, or syphilis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This study tests an experimental injection called TVAX-008 for people with chronic hepatitis B who are already on antiviral therapy. It aims to see if it can help control the virus and potentially lead to a functional cure.
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
Hear when a new Chronic Hepatitis B Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.